Total Payments
$152,875
2023 Payments
$23.02
Companies
9
Transactions
37
Payment Breakdown by Category
Research$148,279 (97.0%)
Travel$2,135 (1.4%)
Food & Beverage$1,440 (0.9%)
Consulting$1,000 (0.7%)
Gifts$20.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $148,279 | 11 | 97.0% |
| Travel and Lodging | $2,135 | 8 | 1.4% |
| Food and Beverage | $1,440 | 16 | 0.9% |
| Consulting Fee | $1,000 | 1 | 0.7% |
| Gift | $20.00 | 1 | 0.0% |
Payments by Type
Research
$148,279
11 transactions
General
$4,596
26 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $147,803 | 5 | $0 (2022) |
| Merck Sharp & Dohme LLC | $2,485 | 11 | $0 (2021) |
| PFIZER INC. | $1,783 | 8 | $0 (2021) |
| Takeda Pharmaceuticals U.S.A., Inc. | $448.73 | 5 | $0 (2020) |
| Gilead Sciences, Inc. | $140.29 | 2 | $0 (2019) |
| Alkermes, Inc. | $94.98 | 1 | $0 (2018) |
| Allergan Inc. | $60.25 | 2 | $0 (2018) |
| Valeant Pharmaceuticals North America LLC | $37.66 | 2 | $0 (2017) |
| INTERCEPT PHARMACEUTICALS, INC. | $23.02 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $23.02 | 1 | INTERCEPT PHARMACEUTICALS, INC. ($23.02) |
| 2022 | $48.00 | 1 | Eli Lilly and Company ($48.00) |
| 2021 | $1,038 | 3 | Merck Sharp & Dohme LLC ($1,000) |
| 2020 | $145,979 | 7 | Eli Lilly and Company ($145,530) |
| 2019 | $5,010 | 17 | Eli Lilly and Company ($2,207) |
| 2018 | $711.51 | 5 | PFIZER INC. ($584.26) |
| 2017 | $65.64 | 3 | Valeant Pharmaceuticals North America LLC ($37.66) |
All Payment Transactions
37 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/05/2023 | INTERCEPT PHARMACEUTICALS, INC. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $23.02 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $48.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) | ||||||
| 12/08/2021 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/15/2021 | Eli Lilly and Company | — | — | In-kind items and services | $18.14 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) | ||||||
| 06/04/2021 | PFIZER INC. | — | Gift | In-kind items and services | $20.00 | General |
| 03/03/2020 | Eli Lilly and Company | — | — | Cash or cash equivalent | $142,441.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) | ||||||
| 01/10/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $74.00 | Research |
| Study: A PHASE 1B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY OF 2 SINGLE INTRAVENOUS INFUSION DOSES OF TAK-925 IN SUBJECTS WITH OBSTRUCTIVE SLEEP APNEA WHO ARE EXPERIENCING EXCESSIVE DAYTIME SLEEPINESS DESPITE ADEQUATE USE OF CPAP | ||||||
| 01/10/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $50.00 | Research |
| Study: A PHASE 1B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY OF 2 SINGLE INTRAVENOUS INFUSION DOSES OF TAK-925 IN SUBJECTS WITH OBSTRUCTIVE SLEEP APNEA WHO ARE EXPERIENCING EXCESSIVE DAYTIME SLEEPINESS DESPITE ADEQUATE USE OF CPAP | ||||||
| 01/10/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $50.00 | Research |
| Study: A PHASE 1B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY OF 2 SINGLE INTRAVENOUS INFUSION DOSES OF TAK-925 IN SUBJECTS WITH OBSTRUCTIVE SLEEP APNEA WHO ARE EXPERIENCING EXCESSIVE DAYTIME SLEEPINESS DESPITE ADEQUATE USE OF CPAP | ||||||
| 01/10/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $25.00 | Research |
| Study: A PHASE 1B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY OF 2 SINGLE INTRAVENOUS INFUSION DOSES OF TAK-925 IN SUBJECTS WITH OBSTRUCTIVE SLEEP APNEA WHO ARE EXPERIENCING EXCESSIVE DAYTIME SLEEPINESS DESPITE ADEQUATE USE OF CPAP | ||||||
| 01/08/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $249.73 | Research |
| Study: A PHASE 1B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY OF 2 SINGLE INTRAVENOUS INFUSION DOSES OF TAK-925 IN SUBJECTS WITH OBSTRUCTIVE SLEEP APNEA WHO ARE EXPERIENCING EXCESSIVE DAYTIME SLEEPINESS DESPITE ADEQUATE USE OF CPAP | ||||||
| 01/02/2020 | Eli Lilly and Company | — | — | In-kind items and services | $3,088.87 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) | ||||||
| 09/17/2019 | Eli Lilly and Company | — | — | In-kind items and services | $2,206.69 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) | ||||||
| 09/13/2019 | Merck Sharp & Dohme Corporation | MK-8591 (Drug) | Travel and Lodging | In-kind items and services | $166.94 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/13/2019 | Merck Sharp & Dohme Corporation | MK-8591 (Drug) | Food and Beverage | In-kind items and services | $54.79 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/13/2019 | Merck Sharp & Dohme Corporation | MK-8591 (Drug) | Food and Beverage | In-kind items and services | $52.18 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/13/2019 | Merck Sharp & Dohme Corporation | MK-8591 (Drug) | Food and Beverage | In-kind items and services | $44.35 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/12/2019 | Merck Sharp & Dohme Corporation | MK-8591 (Drug) | Travel and Lodging | In-kind items and services | $166.94 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/12/2019 | Merck Sharp & Dohme Corporation | MK-8591 (Drug) | Food and Beverage | In-kind items and services | $91.32 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 08/08/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $15.29 | General |
| 07/17/2019 | Gilead Sciences, Inc. | Epclusa (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: HCV | ||||||
| 03/27/2019 | Merck Sharp & Dohme Corporation | MK-7264 (Drug) | Food and Beverage | In-kind items and services | $42.00 | General |
| Category: RESPIRATORY | ||||||
| 03/27/2019 | Merck Sharp & Dohme Corporation | MK-7264 (Drug) | Food and Beverage | In-kind items and services | $40.00 | General |
| Category: RESPIRATORY | ||||||
| 03/26/2019 | Merck Sharp & Dohme Corporation | MK-7264 (Drug) | Travel and Lodging | In-kind items and services | $639.11 | General |
| Category: RESPIRATORY | ||||||
| 03/26/2019 | Merck Sharp & Dohme Corporation | MK-7264 (Drug) | Travel and Lodging | In-kind items and services | $187.02 | General |
| Category: RESPIRATORY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) | Eli Lilly and Company | $147,803 | 5 |
| A PHASE 1B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY OF 2 SINGLE INTRAVENOUS INFUSION DOSES OF TAK-925 IN SUBJECTS WITH OBSTRUCTIVE SLEEP APNEA WHO ARE EXPERIENCING EXCESSIVE DAYTIME SLEEPINESS DESPITE ADEQUATE USE OF CPAP | Takeda Pharmaceuticals U.S.A., Inc. | $448.73 | 5 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER | Allergan Inc. | $27.98 | 1 |
About Dr. Howard Schwartz, M.D
Dr. Howard Schwartz, M.D is a Gastroenterology healthcare provider based in Tavernier, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/15/2005. The National Provider Identifier (NPI) number assigned to this provider is 1942286588.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Howard Schwartz, M.D has received a total of $152,875 in payments from pharmaceutical and medical device companies, with $23.02 received in 2023. These payments were reported across 37 transactions from 9 companies. The most common payment nature is "" ($148,279).
Ad
Practice Information
- Specialty Gastroenterology
- Location Tavernier, FL
- Active Since 12/15/2005
- Last Updated 04/08/2024
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1942286588
Products in Payments
- MK-7264 (Drug) $908.13
- PREVNAR - 13 (Biological) $799.27
- MK-8591 (Drug) $576.52
- Epclusa (Drug) $125.00
- XIFAXAN (Drug) $37.66
- OCALIVA (Drug) $23.02
- INFLECTRA (Biological) $10.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.